2 parties interested at 20.7 and 20.8c PPS. These are low ball offers to fully acquire the technology.
the parties have both priced in risk of execution getting the covid test to commercialisation. They see huge upside in this technology.
Just because a takeover bid gets knocked back doesn’t mean we won’t find commercial terms with these organisations moving forward.
pfizer and Resapp have been jointly developing a covid test for the past months. There’s obvious signs this technology is working and close to commercialisation or Pfizer would just start their own journey without us.
Still voting No as I believe we will have partners lining up now that Pfizer has validated the technology on a global scale by the takeover bid.
As management have said the test is only likely to take another $1M to refine with additional clinical studies already underway.
- Forums
- ASX - By Stock
- RAP
- Why you should vote YES - a professional investor's perspective
Why you should vote YES - a professional investor's perspective, page-42
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
DVP
Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
Add RAP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable